The present disclosure relates generally to apparatus and methods for providing electrical energy for tissue treatment.
U.S. Pat. No. 6,326,177 to Schoenbach et al., which is incorporated by reference herein in its entirety, describes an apparatus and method for intracellular electro-manipulation, including tissue treatment, using ultra short pulses. As taught by Schoenbach et al., target cells are subjected to one or more ultra short electric field pulses.
A general object of the subject matter disclosed herein is to therefore provide an improved delivery device for delivery of electrical energy for the treatment of a tissue condition.
Another general object of the subject matter disclosed herein is to provide an improved pulse generator for providing the electrical energy to the delivery device.
A further object of the subject matter disclosed herein is to provide a delivery device for delivery of electrical energy for the treatment of a tissue condition which is in the form of a dual or multiple needle assembly for penetration of the dermis.
Yet another object of the subject matter disclosed herein is to provide a dual or multiple needle assembly for the treatment of a tissue condition which is disposable.
A still further object of the subject matter disclosed herein is to provide insulation about portions of the dual or multiple needle assembly to protect the dermis during treatment of subcutaneous tissue.
Another object of the subject matter disclosed herein is to provide a pulse generator which generates low energy, high voltage pulses of short duration.
The subject matter disclosed herein is directed to an apparatus, systems and methods for treating a tissue condition. In one embodiment, apparatus for providing electrical energy to human tissue to treat a tissue condition includes a high voltage pulse generator for generating a short high voltage pulse of energy at a pair of output terminals, a delivery device receives the short high voltage pulse of energy from the pulse generator, the delivery device preferably includes at least a pair of needle electrodes for penetrating into the human tissue and for delivering the short high voltage pulse of energy to tissue disposed between the needle electrodes.
The pair of needle electrodes of the delivery device preferably have uncoated ends, and have an insulative coating applied about proximal portions of the needle electrodes. The insulative coating may consist of parylene, polyimide, polyester, diamond, Teflon, or combinations of such materials, or another insulating material. When in use during a tissue treatment procedure, the uncoated portions of the needle electrodes are located in sub-dermal tissue and the coated portions of the needle electrodes are located in dermis. The short high voltage pulse may be in the range of about 10 to 500 nanoseconds in duration, and may provide average electric field strength of about 10 to 50 kilovolts/centimeter in the tissue. The tissue treatment procedure may include an intracellular electro-manipulation treatment or a plasma spark discharge.
In another embodiment, multiple needle electrodes will be used in an array. At any time, two selected electrodes will have the desired voltage applied across them. The selected electrodes may be selected with a switch, for example, based upon electromechanical relays.
In another embodiment, the subject matter disclosed herein is directed to a system for providing electrical energy to human tissue to treat a tissue condition. The system preferably includes a high voltage pulse generator for generating a short high voltage pulse of energy at a pair of output terminals, the pulse generator includes a spark gap which contains a pressurized gas and which emits a spark when the voltage across the spark gap exceeds the dielectric strength of the gas in the spark gap, a sensor for sensing the pressure of the pressurized gas in the spark gap and for providing a pressure signal related to the sensed pressure, means for adjusting the pressure in the spark gap to modify the magnitude of the voltage of the short high voltage pulse generated by the pulse generator, and a delivery device for receiving the short high voltage pulse of energy from the pulse generator and for applying the short high voltage pulse of energy to the tissue.
The means for adjusting the pressure in the spark gap may further include a controllable gas pressure regulator to supply gas pressure to the spark gap, means for selecting an initial voltage magnitude for the short high voltage pulse, means for determining the actual voltage magnitude of the short high voltage pulse and for providing a signal representative of the actual voltage magnitude of the short high voltage pulse, and a data processor for receiving the signal representative of the voltage magnitude of the short high voltage pulse, the data processor determining any difference between the selected voltage magnitude and the actual voltage magnitude of the short high voltage pulse, and the data processor supplying a corrective signal to the controllable gas pressure regulator to change the gas pressure in the spark gap to decrease the voltage magnitude of the short high voltage pulse if the actual voltage magnitude is greater than the selected voltage magnitude or to increase the voltage magnitude of the short high voltage pulse if the actual voltage magnitude is less than the selected voltage magnitude.
A triggered spark gap may also be employed. In this embodiment, the pressure in the spark gap switch is held high enough so that it does not trigger without an external stimulus. An external stimulus is provided when it is desired to turn on the spark gap switch, for example, at a preprogrammed interval and at the desired voltage after the operator presses the switch to impart the treatment.
The means for providing a signal representative of the actual voltage magnitude may be a resistor divider or a pulse transformer. The data processor may be selected from a group consisting of a field programmable gate array, a complex programmable logic device, a microprocessor or a microcontroller. The pulse generator may be a Blumlein pulse generator. The delivery device may have similar characteristics and properties as presented above.
The apparatus and system may further include a vacuum in the delivery device to assist in keeping a bottom face of the delivery device in contact with the human tissue during the treatment. A retractable needle support may protect the pair of needle electrodes from bending during insertion of the pair of needle electrodes into the human tissue. The ends of the pair of needle electrodes may be retracted into the delivery device and the ends of the pair of needle electrodes may be quickly forced into the human tissue upon actuation of the delivery device.
A further embodiment of the subject matter disclosed herein is directed to methods for providing electrical energy to human tissue to treat a tissue condition. The method includes the steps of generating a short high voltage pulse of energy at a pair of output terminals with a high voltage pulse generator, emitting a spark when the voltage across a spark gap associated with the pulse generator exceeds the dielectric strength of pressurized gas in the spark gap, sensing the pressure of the gas in the spark gap, providing a pressure signal related to the sensed pressure, adjusting the pressure in the spark gap to modify the magnitude of the voltage of the short high voltage pulse generated by the pulse generator, receiving the short high voltage pulse of energy from the pulse generator at a delivery device, and applying the short high voltage pulse of energy to the tissue.
The methods may include the further steps of supplying gas pressure to the spark gap from a controllable gas pressure regulator, selecting an initial voltage magnitude for the short high voltage pulse, determining the actual voltage magnitude of the short high voltage pulse, providing a signal representative of the actual voltage magnitude of the short high voltage pulse, receiving the signal representative of the voltage magnitude of the short high voltage pulse at a data processor, determining any difference between the selected voltage magnitude and the actual voltage magnitude of the short high voltage pulse and supplying a corrective signal to the controllable gas pressure regulator to change the gas pressure in the spark gap to decrease the voltage magnitude of the short high voltage pulse if the actual voltage magnitude is greater than the selected voltage magnitude or to increase the voltage magnitude of the short high voltage pulse if the actual voltage magnitude is less than the selected voltage magnitude.
The step of providing a signal representative of the actual voltage magnitude of the short high voltage pulse may be provided by a resistor divider or by a pulse transformer. Still further steps of the methods may include one or more of the steps of selecting the data processor from a group consisting of a field programmable gate array, a complex programmable logic device, a microprocessor or a microcontroller, disposing an impedance between the high voltage pulse generator and the delivery device to limit the current associated with the short high voltage pulse of energy when the tissue has high conductivity condition, providing a pair of needle electrodes in the delivery device for penetrating into the human tissue, delivering the short high voltage pulse of energy to tissue disposed between the needle electrodes, providing the needle electrodes with uncoated ends, and providing an insulative coating about proximal portions of the needle electrodes.
The methods may further include the step of providing a vacuum in the delivery device to assist in keeping a bottom face of the delivery device in contact with the human tissue during the treatment. Still further steps may include disposing a pair of needle electrodes in said delivery device for penetrating into the human tissue and for delivering the short high voltage pulse of energy to tissue disposed between the needle electrodes, retracting the ends of the pair of needle electrodes into the delivery device, and forcing the ends of the pair of needle electrodes into the human tissue upon actuation of the delivery device. Additional steps may include disposing a pair of needle electrodes in the delivery device for penetrating into the human tissue and for delivering the short high voltage pulse of energy to tissue disposed between the needle electrodes, providing a retractable needle support to protect the pair of needle electrodes from bending during insertion of the pair of needle electrodes into the human tissue, extending the retractable needle support about the ends of the pair of needle electrodes, and retracting said retractable needle support into the delivery device as the pair of needle electrodes are inserted into the human tissue.
The subject matter disclosed herein, together with its objects and the advantages thereof, may best be understood by reference to the following description taken in conjunction with the accompanying drawings, in which like reference numerals identify like elements in the figures, and in which:
It will be understood that the subject matter disclosed herein may be embodied in other specific forms without departing from the spirit thereof. The present examples and embodiments, therefore, are to be considered in all respects as illustrative and not restrictive, and the subject matter disclosed is not to be limited to the details presented herein.
The apparatus, systems and methods of the subject matter disclosed herein deliver pulsed electrical fields to sub dermal tissue of a human being. One such use is for the treatment of cellulite, by targeting fat cells and connective tissue. Other uses may include potential treatment of cancer, such as leukemia, may also be of interest.
One embodiment of an electrical pulse delivery device, generally designated 100, is shown in
A portion of delivery device 100 includes a generally cylindrical housing 106. As seen in
Preferably, the dual needle assembly 114 is disposable and is sealed for hygienic reasons. As shown in
Needles 104 and 105 are preferably micro-needles, which may be made, for example, from solid 30 gauge stainless steel (316) stock. The tips of needles 104 and 105 may be hypodermic-style. That is, the tips may be formed with cutting edges to facilitate relatively painless and easy penetration of the skin.
The purpose of coating 228 at the upper end 220 of needle 104 is to avoid application of stronger electrical fields by delivery device 100 to dermal tissues while the lower uncoated end 222 is applying electrical fields to sub dermal tissue, such as fat cells and connective tissue called septae. Coating 228 is preferably relatively uniform in thickness and without any voids, such as pinholes. For example, coating 228 may be a parylene coating, which is deposited by a vapor-phase deposition polymerization process. Parylene has a low coefficient of friction, very low permeability to moisture and a high dielectric strength. Other examples for the coating 228 include polyimide, polyester, diamond, Teflon and siloxane. While needle 104 is shown in
For example, the needles 104 and 105 may extend about 5 mm to 15 mm, and, typically about 8 mm, from the bottom surface 112 of delivery device 100, with the proximal 3 mm to 5 mm of needles 104 and 105 having the insulating parylene coating 228. The parylene coating 228 is intended to extend through the dermis during a treatment procedure, thus protecting the dermis by substantially reducing the electrical field between needles 104 and 105 in the vicinity of the dermis. By way of example, the dual-needle delivery device 100 discussed herein may subject the target cells to a pulse in the range of 10 nanoseconds to 500 nanoseconds (10×10−9 seconds to 500×10−9 seconds) having an average electric field strength (“E”) of about 10 kV/cm to 50 kV/cm, and, typically of about 30 kV/cm, at a pulse rate of about 1 to 10 pulses per second.
With reference to
An alternate multiple needle array 115, which provides more than two needles 104-105 in the dual needle assembly 114, is shown in
As described above, the system delivers very short pulses of low energy to the tissue being treated. The schematic diagram in
Inner conductors 310 and 312 of coaxial sections 306 and 307 connect to one of the leads of the spark gap 318. The other lead of spark gap 318 connects to the outer sheath 313 of coaxial section 307. Near coaxial sections 308 and 309, the outer sheaths 311 and 313 of coaxial sections 306 and 307 are grounded, as well as the inner conductors 314 and 316 of coaxial sections 308 and 309. At the opposite ends of coaxial sections 308 and 309, the outer sheaths 315 and 317 are connected together at a node 325. Inner conductor 314 of coaxial section 308 is connected to a pair of resistors 320 and 321, and inner conductor 316 of coaxial section 309 is similarly connected to another pair of resistors 322 and 323. Opposite ends of resistors 320 and 322 are connected to node 325. Opposite ends of resistors 321 and 323 are connected to needles 104 and 105, respectively. Collectively, resistors 320-323 form a balanced resistor network at the output of pulse generator 300.
The spark gap 318 may be filled with nitrogen or any other suitable gas. The internal pressure of the nitrogen in the spark gap may be regulated to control the voltage at which the spark gap breaks down, thereby also controlling the amount of energy delivered to the needles 104 and 105 by the pulse generator 300. When the spark gap breaks down, a high voltage, short duration pulse will be delivered to the needles through the balanced resistor network consisting of resistors 320-323. In an embodiment, all of resistors 320-323 may be about 50 ohms. The magnitude of the voltage delivered to the patient is determined by the spark gap 318. The spark gap will breakdown when the voltage across its electrodes exceeds the dielectric strength of the gas in the spark gap. The dielectric strength of the gas is controlled by the gaseous pressure within the spark gap. Thus, controlling the gaseous pressure also controls the magnitude of the voltage delivered.
In order to safely and reliably deliver short high-voltage pulses to a patient during a treatment procedure, adequate controls and monitors are required. The subject matter disclosed herein is also concerned with such controls and monitors. The first set of controls relate to ensuring that the voltage delivered to the patient is correct and accurate. The voltage delivered to the patient is selected by the operator through a user interface module, generally designated 400 in
Associated with user interface module 400 is a high voltage control module 420. Module 420 may include a high voltage enable switch 422, a probe (also referred to herein as delivery device 100) calibration connection 424, a high voltage output 426 for supplying the high voltage pulses to delivery device 100, and a low voltage connection 428 for the delivery device 100. A regulator 432 monitors and supplies nitrogen gas to spark gap 318 from a source of compressed nitrogen 430.
CPLD 504 enables the HV power supply 302 via line 510. Signal conditioning circuitry 512 monitors the output voltage of the HV power supply on line 513. In this respect, signal conditioning circuitry 512 may have a voltage reference for comparison purposes. An analog to digital converter (ADC) 514 supplies the monitored information to CPLD 504 via a serial peripheral interface (SPI) bus. The SPI bus is also routed to other portions of the circuitry 500, such as to an isolated SPI interface 516 which may supply information to external sources, such as a master data controller 518.
Digital information concerning falling edge threshold and rising edge threshold is provided from peak detector 526, via lines 528 and 529, to a digital to analog converter (DAC) 524. DAC 524 then provides a pressure set signal on line 530 to pressure control 432 to regulate the pressure of nitrogen in the spark gap 318. As previously explained, control of the pressure in spark gap 318 controls the magnitude of the high voltage pulses generated by pulse generator 300. Pressure feedback information is provided from pressure control 432 on line 531 to the signal conditioning and thence to ADC where it is sent via the SPI bus to CPLD 504.
The CPLD or microprocessor 504 controls the gas pressure regulator 432 in setting and monitoring the gaseous pressure within the spark gap 318. The microprocessor also monitors the voltages going to the Blumlein pulse generator 300 and the voltage across the load resistors 320-323 on the output of the pulse generator using resistor dividers, pulse transformer 506 and analog to digital converter 514. Prior to use on the patient, the delivered voltage at the needles 104-105 is adjusted to ensure a proper value. This process starts by setting the spark gap pressure to an empirically generated first guess estimated to give the proper voltage. The Blumlein pulse generator 300 is fired and the pulse generator voltages are monitored. The pressure is then adjusted based on the difference between the measured output voltage and the desired output voltage. The adjustment process continues until the difference between the measured and desired is within an acceptable level.
The adjustment is preferably proportional control. However, the adjustment could also include differential and integral control. The control can be based on either the monitored pulse generator input or output signal. Using the pulse generator input signal requires monitoring the input voltage and holding the peak value from the time that the high voltage power supply (HVPS) 302 is activated until the pulse is delivered at the needles 104-105. Delivery of the pulse can be detected by either sensing a rapid decrease in the pulse generator input, a pulse on the pulse generator output or an optical signal from the spark gap. Using the pulse generator output signal may require detecting the rising and falling edges of the pulse and averaging the values between these two edges.
An alternate method for monitoring the voltage is to implement a calibration port 424 on the system. This calibration port 424 allows the distal end of the delivery device 100 to be connected to the console 420. The distal electrode voltage is then monitored and the spark gap pressure is controlled to ensure that the distal electrode voltage matches the desired output voltage within appropriate limits. This method will compensate for any losses or changes to the voltage induced by the patient cable and/or the delivery device.
A second set of controls is related to controlling the pulse delivery rate. The control of the pulse delivery rate is selected by the operator through the user interface 400. The microprocessor 504 controls the delivery of each pulse by commanding the HVPS 302 to go to a predetermined high voltage level that is selected to be higher than the desired voltage delivered to the patient. In this embodiment, the microprocessor controls the HVPS command through a field programmable gate array (FPGA) 504. This FPGA buffers the command to the HVPS 302 and controls the slope of the command to mitigate against excessive overshoot of the HVPS output. The output of the HVPS is feed into the pulse generator 300 through a series resistor and appropriate protection diodes. The microprocessor 504 will initiate these pulses at the rate determined by the user interface 400, such as by selection on screen 408. Several monitors ensure that the pulses delivered are within predetermined parameters. If any of these monitors indicate that the pulse has not been delivered, microprocessor 504 will inhibit any new pulses from being initiated and will alert the operator to the problem.
One risk for any high voltage delivery system is that some other component in the system breaks down at a lower voltage than the spark gap 318. If this occurs, no pulse, an improperly shaped pulse or a lower voltage pulse could be delivered to the patient. If any failures within the system are detected or if delivered pulses are not within established parameters, subsequent delivery of pulses will be terminated and the operator will be alerted.
In accordance with another aspect, the subject matter disclosed herein may be used by a physician to treat cellulite by inducing selective adipocyte death in the subcutaneous fat layer (SFL), or cutting of collageneous septae, or both, such as by plasma spark discharge. Adipocyte death may be caused by apoptosis or necrosis, both considered cell lysis. The dead adipocytes will be naturally reabsorbed by the body. Fewer adipocytes in the SFL will reduce the pressure on the dermis, blood vessels and lymphatic system in the affected area, which will typically lead to an improved cosmetic experience. The subject matter disclosed herein may also have an effect of cutting or ablating or denaturing septae that tether the dermis to the underlying fascia. These effects on the septae will lead to improvement in the appearance of cellulite dimples, for example, by releasing the tension on the dermis.
In accordance with a further aspect of the subject matter disclosed herein, needles 104-105 may be force assisted for insertion into the skin. One of the problems associated with small gauge needles, such as about 30 gauge needles, is that they tend to bend while insertion into the skin if the needles are not substantially perpendicular to the skin during insertion. Thus, care must be taken while inserting the needles into the skin to apply forces perpendicular to the skin surface, and in the direction of the needles, to avoid bending the needles. Thus, in accordance with another aspect of the subject matter disclosed herein, the needles 104-105 may be retractable into the delivery device 100. Upon actuation, the needles 104-105 are quickly forced or shot out to their full distal position, as illustrated in
A flowchart 900 in
In accordance with yet another aspect of the subject matter disclosed herein, an energy delivery device 600 may be provided with a retractable needle support 610 or 620, as illustrated by the embodiments shown in
A desirable characteristic of the retractable support 610 is to house the needles 104-105 in a manner which protects the needles from bending or from encountering other damage when not in use. For example, the retractable support 610 may be a tube-like structure of a length sufficient to cover the ends of the needles 104-105, with internal diameters sufficiently large to accommodate the smaller diameter needles, but also of sufficiently small diameter to prevent any significant bending of the needles 104-105 during insertion. Retractable support 610 may be of any suitable shape, such as of a modified oval cross-sectional shape shown in
Alternatively, a separate retractable support 620 in
Either of the retractable supports 610 or 620 may be biased by light pressure supplied, such as by a spring 622 shown in
In accordance with another aspect of the subject matter disclosed herein, the delivery device 100 may utilize vacuum-assisted skin engagement. Current and prior art procedures require the physician to hold a delivery device perpendicular to the skin with moderate pressure. If the orientation of the delivery device changes, or if the pressure of the delivery device 100 against the surface of the skin changes, the electrical conditions between the adipose tissue, the pulse generator 300 and the two needles 104-105 may change, resulting in a higher than desired current level. Additionally, air may become entrapped between the needles which may provide a leakage current path.
Illustrated in
Another embodiment of a disposable needle assembly 720 is shown in
However, when the bottom face 704 of the outer sleeve 724 is applied against the skin of a patient, the foam rings 728-729 are compressed such that needles 104-105 penetrate the skin. At the same time, the upper end 725 of outer sleeve 724 moves upwardly within the annular recess 726. If desired, the limit of needle penetration in the skin can be provided when the upper end 725 contacts the end of the annular groove 726, or when the foam rings 728-729 are fully compressed. The foam rings may be of a foam material which has memory to return to its uncompressed state when a treatment is completed. For example, foam rings 728-729 may be made of a closed cell foam material.
Another embodiment for protecting for the needles 104-105 is shown in
While particular embodiments of the subject matter disclosed herein have been shown and described, it will be obvious to those skilled in the art that changes and modifications may be made therein without departing from the invention in its broader aspects.
This patent application claims the benefit of, and the right of priority to, U.S. provisional patent application Ser. No. 61/050,814, filed on May 6, 2008.
Number | Name | Date | Kind |
---|---|---|---|
1645215 | Bauer | Oct 1927 | A |
1814791 | Ende | Jul 1931 | A |
1916722 | Ende | Jul 1933 | A |
2185367 | Blumlein | Jan 1940 | A |
3551677 | Brewster | Dec 1970 | A |
3571746 | DeTemple et al. | Mar 1971 | A |
4016886 | Doss et al. | Apr 1977 | A |
4667161 | Wilcox | May 1987 | A |
4878793 | Hewison | Nov 1989 | A |
4917093 | Dufresne et al. | Apr 1990 | A |
4955378 | Grasso | Sep 1990 | A |
4969468 | Byers et al. | Nov 1990 | A |
5019034 | Weaver et al. | May 1991 | A |
5085639 | Ryan | Feb 1992 | A |
5088982 | Ryan | Feb 1992 | A |
5118969 | Ikezi et al. | Jun 1992 | A |
5137817 | Busta et al. | Aug 1992 | A |
5138270 | Nakata et al. | Aug 1992 | A |
5211660 | Grasso | May 1993 | A |
5382240 | Lam | Jan 1995 | A |
5389069 | Weaver | Feb 1995 | A |
5458597 | Edwards et al. | Oct 1995 | A |
5464386 | Hofmann | Nov 1995 | A |
5527352 | Vona | Jun 1996 | A |
5536267 | Edwards et al. | Jul 1996 | A |
5593429 | Ruff | Jan 1997 | A |
5630426 | Eggers et al. | May 1997 | A |
5660836 | Knowlton | Aug 1997 | A |
5674267 | Mir et al. | Oct 1997 | A |
5688233 | Hofmann et al. | Nov 1997 | A |
5697882 | Eggers | Dec 1997 | A |
5702359 | Hofmann et al. | Dec 1997 | A |
5775753 | Tetelboim | Jul 1998 | A |
5778894 | Dorogi et al. | Jul 1998 | A |
5810762 | Hofmann | Sep 1998 | A |
5868744 | Willmen | Feb 1999 | A |
5871469 | Eggers | Feb 1999 | A |
5871524 | Knowlton | Feb 1999 | A |
5885211 | Eppstein et al. | Mar 1999 | A |
5911223 | Weaver et al. | Jun 1999 | A |
5928159 | Eggers et al. | Jul 1999 | A |
5947964 | Eggers et al. | Sep 1999 | A |
5954717 | Behl et al. | Sep 1999 | A |
5968006 | Hofmann | Oct 1999 | A |
5968041 | Edwards | Oct 1999 | A |
5993434 | Dev et al. | Nov 1999 | A |
6010613 | Walters et al. | Jan 2000 | A |
6014584 | Hofmann et al. | Jan 2000 | A |
6027501 | Goble et al. | Feb 2000 | A |
6043066 | Mangano et al. | Mar 2000 | A |
6050992 | Nichols | Apr 2000 | A |
6055453 | Hofmann et al. | Apr 2000 | A |
6068650 | Hofmann et al. | May 2000 | A |
6086585 | Hovda et al. | Jul 2000 | A |
6106524 | Eggers et al. | Aug 2000 | A |
6107699 | Swanson | Aug 2000 | A |
6117660 | Walters et al. | Sep 2000 | A |
6120493 | Hofmann | Sep 2000 | A |
6135990 | Heller et al. | Oct 2000 | A |
6135998 | Palanker | Oct 2000 | A |
6149620 | Baker | Nov 2000 | A |
6174308 | Goble et al. | Jan 2001 | B1 |
6176857 | Ashley | Jan 2001 | B1 |
6181964 | Hofmann et al. | Jan 2001 | B1 |
6190381 | Olsen | Feb 2001 | B1 |
6208893 | Hofmann | Mar 2001 | B1 |
6210402 | Olsen et al. | Apr 2001 | B1 |
6212433 | Behl | Apr 2001 | B1 |
6216034 | Hofmann et al. | Apr 2001 | B1 |
6224592 | Eggers et al. | May 2001 | B1 |
6228078 | Eggers et al. | May 2001 | B1 |
6264652 | Eggers et al. | Jul 2001 | B1 |
6296638 | Davison et al. | Oct 2001 | B1 |
6309387 | Eggers et al. | Oct 2001 | B1 |
6312428 | Eggers et al. | Nov 2001 | B1 |
6326177 | Schoenbach et al. | Dec 2001 | B1 |
6334856 | Allen et al. | Jan 2002 | B1 |
6346103 | Korsec et al. | Feb 2002 | B1 |
6350262 | Ashley | Feb 2002 | B1 |
6377854 | Knowlton | Apr 2002 | B1 |
6377855 | Knowlton | Apr 2002 | B1 |
6379353 | Nichols | Apr 2002 | B1 |
6381497 | Knowlton | Apr 2002 | B1 |
6381498 | Knowlton | Apr 2002 | B1 |
6387380 | Knowlton | May 2002 | B1 |
6402742 | Blewett et al. | Jun 2002 | B1 |
6405090 | Knowlton | Jun 2002 | B1 |
6413255 | Stern | Jul 2002 | B1 |
6413256 | Truckai et al. | Jul 2002 | B1 |
6416507 | Eggers et al. | Jul 2002 | B1 |
6416508 | Eggers et al. | Jul 2002 | B1 |
6425873 | Marchitto et al. | Jul 2002 | B1 |
6425912 | Knowlton | Jul 2002 | B1 |
6430446 | Knowlton | Aug 2002 | B1 |
6443914 | Costantino | Sep 2002 | B1 |
6453202 | Knowlton | Sep 2002 | B1 |
6453203 | Yamazaki | Sep 2002 | B1 |
6461350 | Underwood et al. | Oct 2002 | B1 |
6461354 | Olsen et al. | Oct 2002 | B1 |
6461378 | Knowlton | Oct 2002 | B1 |
6470216 | Knowlton | Oct 2002 | B1 |
6475191 | Tamura et al. | Nov 2002 | B2 |
6482201 | Olsen et al. | Nov 2002 | B1 |
6491669 | Ebara | Dec 2002 | B2 |
D469179 | Nakagami | Jan 2003 | S |
6503231 | Prausnitz et al. | Jan 2003 | B1 |
6514248 | Eggers et al. | Feb 2003 | B1 |
6516223 | Hofmann | Feb 2003 | B2 |
6520950 | Hofmann et al. | Feb 2003 | B1 |
6567694 | Hayakawa | May 2003 | B2 |
6569149 | Dev et al. | May 2003 | B2 |
6569159 | Edwards et al. | May 2003 | B1 |
6572613 | Ellman et al. | Jun 2003 | B1 |
6582237 | Jacobson | Jun 2003 | B2 |
6589786 | Mangano et al. | Jul 2003 | B1 |
6603998 | King et al. | Aug 2003 | B1 |
6616631 | Takagi | Sep 2003 | B2 |
6632193 | Davison et al. | Oct 2003 | B1 |
6632220 | Eggers et al. | Oct 2003 | B1 |
6632221 | Edwards et al. | Oct 2003 | B1 |
6637998 | Langan et al. | Oct 2003 | B2 |
6638254 | Nakagami | Oct 2003 | B2 |
6641580 | Edwards et al. | Nov 2003 | B1 |
6656167 | Numao | Dec 2003 | B2 |
6673072 | Garito et al. | Jan 2004 | B1 |
6676638 | Takagi | Jan 2004 | B2 |
6697670 | Chomenky et al. | Feb 2004 | B2 |
6730075 | Palanker | May 2004 | B2 |
6733485 | Whitehurst et al. | May 2004 | B1 |
6743211 | Prausnitz et al. | Jun 2004 | B1 |
6760627 | Carter et al. | Jul 2004 | B2 |
6766202 | Underwood et al. | Jul 2004 | B2 |
6773431 | Eggers et al. | Aug 2004 | B2 |
6780178 | Palanker | Aug 2004 | B2 |
6782283 | Schmidt et al. | Aug 2004 | B2 |
6785569 | Schmidt et al. | Aug 2004 | B2 |
6786891 | Hiejima | Sep 2004 | B2 |
6795728 | Chornenky et al. | Sep 2004 | B2 |
6821274 | McHale et al. | Nov 2004 | B2 |
6831377 | Yampolsky et al. | Dec 2004 | B2 |
6855127 | Nakagami | Feb 2005 | B2 |
6881213 | Ryan et al. | Apr 2005 | B2 |
6889089 | Behl et al. | May 2005 | B2 |
6892099 | Jaafar et al. | May 2005 | B2 |
6896672 | Eggers et al. | May 2005 | B1 |
6913605 | Fletcher | Jul 2005 | B2 |
6918907 | Kelly et al. | Jul 2005 | B2 |
6920883 | Bessette et al. | Jul 2005 | B2 |
6921399 | Carmel et al. | Jul 2005 | B2 |
6923793 | Ishida | Aug 2005 | B2 |
6949096 | Davison | Sep 2005 | B2 |
6961603 | Merilainen | Nov 2005 | B2 |
6974453 | Woloszko et al. | Dec 2005 | B2 |
6994706 | Chornenky et al. | Feb 2006 | B2 |
7004942 | Laird et al. | Feb 2006 | B2 |
7006874 | Knowlton et al. | Feb 2006 | B2 |
7010356 | Jog et al. | Mar 2006 | B2 |
7022121 | Stern | Apr 2006 | B2 |
7048718 | Mithiue | May 2006 | B1 |
7115123 | Knowlton | Oct 2006 | B2 |
7150746 | DeCesare | Dec 2006 | B2 |
7179255 | Lettice et al. | Feb 2007 | B2 |
7189230 | Knowlton | Mar 2007 | B2 |
7217265 | Hennings et al. | May 2007 | B2 |
7229436 | Stern | Jun 2007 | B2 |
7238185 | Palanker | Jul 2007 | B2 |
7270658 | Woloszko et al. | Sep 2007 | B2 |
7278993 | Kelly | Oct 2007 | B2 |
7357802 | Palanker | Apr 2008 | B2 |
20010025176 | Ellsberry et al. | Sep 2001 | A1 |
20010049522 | Eggers et al. | Dec 2001 | A1 |
20020010491 | Schoenbach et al. | Jan 2002 | A1 |
20020034796 | Shastri et al. | Mar 2002 | A1 |
20020077627 | Johnson et al. | Jun 2002 | A1 |
20020087155 | Underwood et al. | Jul 2002 | A1 |
20020120260 | Morris et al. | Aug 2002 | A1 |
20020120261 | Morris et al. | Aug 2002 | A1 |
20020128641 | Underwood et al. | Sep 2002 | A1 |
20020133137 | Hofmann | Sep 2002 | A1 |
20020133149 | Bessette | Sep 2002 | A1 |
20020146831 | Nolan et al. | Oct 2002 | A1 |
20020156471 | Stern et al. | Oct 2002 | A1 |
20020161418 | Wilkens et al. | Oct 2002 | A1 |
20020193784 | McHale et al. | Dec 2002 | A1 |
20020193831 | Smith, III | Dec 2002 | A1 |
20020198485 | Dev et al. | Dec 2002 | A1 |
20030009148 | Hayakawa | Jan 2003 | A1 |
20030009164 | Woloszko et al. | Jan 2003 | A1 |
20030045867 | Marchitto et al. | Mar 2003 | A1 |
20030069618 | Smith, III et al. | Apr 2003 | A1 |
20030083724 | Jog et al. | May 2003 | A1 |
20030088243 | Carmel et al. | May 2003 | A1 |
20030097129 | Davison et al. | May 2003 | A1 |
20030120269 | Bessette et al. | Jun 2003 | A1 |
20030149451 | Chomenky et al. | Aug 2003 | A1 |
20030153960 | Chornenky et al. | Aug 2003 | A1 |
20030170898 | Gundersen et al. | Sep 2003 | A1 |
20030199866 | Stern et al. | Oct 2003 | A1 |
20030212396 | Eggers et al. | Nov 2003 | A1 |
20040000316 | Knowlton et al. | Jan 2004 | A1 |
20040019371 | Jaafar et al. | Jan 2004 | A1 |
20040116986 | Cantoni et al. | Jun 2004 | A1 |
20040153057 | Davison | Aug 2004 | A1 |
20040158288 | Keisari et al. | Aug 2004 | A1 |
20040167458 | Draghia-Akli et al. | Aug 2004 | A1 |
20040181216 | Kelly et al. | Sep 2004 | A1 |
20040181217 | Edwards et al. | Sep 2004 | A1 |
20040186466 | Chornenky et al. | Sep 2004 | A1 |
20040193097 | Hofmann et al. | Sep 2004 | A1 |
20040204669 | Hofmann | Oct 2004 | A1 |
20040210214 | Knowlton | Oct 2004 | A1 |
20040229363 | Nolan et al. | Nov 2004 | A1 |
20040233944 | Dantus et al. | Nov 2004 | A1 |
20040249373 | Gronemyer et al. | Dec 2004 | A1 |
20050080409 | Young et al. | Apr 2005 | A1 |
20050131402 | Ciarrocca et al. | Jun 2005 | A1 |
20050171523 | Rubinsky et al. | Aug 2005 | A1 |
20050182462 | Chornenky et al. | Aug 2005 | A1 |
20050222565 | Manstein | Oct 2005 | A1 |
20050228373 | Kelly et al. | Oct 2005 | A1 |
20050234443 | Rioux et al. | Oct 2005 | A1 |
20050261672 | Deem et al. | Nov 2005 | A1 |
20050273092 | G. et al. | Dec 2005 | A1 |
20050282254 | Lulla et al. | Dec 2005 | A1 |
20060036210 | Zhang et al. | Feb 2006 | A1 |
20060036300 | Kreindel | Feb 2006 | A1 |
20060062074 | Gundersen et al. | Mar 2006 | A1 |
20060064083 | Khalaj et al. | Mar 2006 | A1 |
20060074313 | Slayton et al. | Apr 2006 | A1 |
20060161221 | Blackmore et al. | Jul 2006 | A1 |
20070010811 | Stern et al. | Jan 2007 | A1 |
20070060862 | Sun et al. | Mar 2007 | A1 |
20070060989 | Deem et al. | Mar 2007 | A1 |
20070088413 | Weber | Apr 2007 | A1 |
20070129759 | Colthurst | Jun 2007 | A1 |
20070142881 | Hennings | Jun 2007 | A1 |
20070239156 | Palanker | Oct 2007 | A1 |
20070239260 | Palanker | Oct 2007 | A1 |
20080027428 | Palanker | Jan 2008 | A1 |
20080039832 | Palanker | Feb 2008 | A1 |
20080103529 | Schoenbach et al. | May 2008 | A1 |
20080125774 | Palanker | May 2008 | A1 |
20080140066 | Davison | Jun 2008 | A1 |
20080188846 | Palanker | Aug 2008 | A1 |
Number | Date | Country |
---|---|---|
1844750 | Oct 2007 | EP |
455492 | Oct 1936 | GB |
WO 9962593 | Dec 1999 | WO |
WO 03075777 | Sep 2003 | WO |
Number | Date | Country | |
---|---|---|---|
20090281540 A1 | Nov 2009 | US |
Number | Date | Country | |
---|---|---|---|
61050814 | May 2008 | US |